Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidney Week 2024, the American Society of Nephrology's (ASN) annual meeting, taking place October 23-27 in San Diego, California. Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated diseases.

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

Micron Technology

Regeneron Pharmaceuticals

The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections.

These 3 Stocks Are Screaming Oversold: Seize the Opportunity

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen stock was headed higher Wednesday, to bounce off an 11-year closing low, after the biotechnology company received positive news from regulators about its treatment for kidney-transplant rejections.

Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment

CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for the treatment of late antibody-mediated rejection (AMR) without T-cell mediated rejection in kidney transplant patients. The FDA grants BTD to drug candidates for serious or life-threatening conditions and that have preliminary clinical evidence demonstrating potential to provide substantial improvement over existing therapies. The designation provides additional opportunities to engage the FDA and to support the drug development program through Fast Track designation features.

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from Part B and Part C of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of an investigational higher dose regimen of nusinersen in spinal muscular atrophy (SMA), showing benefits in both individuals previously treated and treatment-naïve to nusinersen with infantile-onset or later-onset SMA. The investigational, higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®). Data to be presented during the World Muscle Society (WMS) 2024 Congress (Oct. 8-12, 2024 in Prague) highlight the potential of this investigational higher dose regimen to help address remaining unmet need in SMA.

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

Amgen

bluebird bio

Bristol-Myers

CRISPR Therapeutics

Editas Medicine

Exact Sciences

Intellia Therapeutics

Pfizer

Recursion Pharmaceuticals

Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and contrarian buying opportunities. AI is revolutionizing drug discovery by significantly speeding up the process and increasing the probability of successful outcomes, making it a game-changer for the biotech sector.

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

SAGE Therapeutics

Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.

Biogen's Lupus Candidate Meets Key Goals in Phase III Study

Biogen Inc.'s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial

Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment

Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.

Biogen-UCB's lupus drug meets main goal of late-stage trial

BRUSSELS and CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe systemic lupus erythematosus (SLE). Dapirolizumab pegol, in addition to standard-of-care (SOC) treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity as assessed by achievement of British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) after 48 weeks versus placebo in addition to SOC. Clinical improvements were observed among key secondary endpoints measuring disease activity and flares.

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

INCHEON, South Korea and CAMBRIDGE, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea2 (aflibercept), also known as SB15.

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™

Biogen Inc. (NASDAQ:BIIB ) Cantor Fitzgerald Global Healthcare Conference Call September 18, 2024 1:20 PM ET Company Participants Chuck Triano - Head, Investor Relations Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. If you could take a seat?

Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)

Despite favorable views on litifilimab, AbbVie's Rinvoq and BMS' Sotyktu capture the most prescriber interest for approval, according to Spherix Global Insights. Despite favorable views on litifilimab, AbbVie's Rinvoq and BMS' Sotyktu capture the most prescriber interest for approval, according to Spherix Global Insights.

US Rheumatologists Believe Biogen's Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data

Eli Lilly

UnitedHealth Group

Health Care Select Sector SPDR Fund

Money has poured into the sector as markets have grown concerned about the economy.

Healthcare Stocks Have Popped. Consider These 2 That Haven't.

Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development

Biogen Board Appoints Two New Independent Directors

Comparable clinical efficacy and safety  in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800) Phase 3 clinical data in totality demonstrates biosimilarity between TOFIDENCE (BAT1806/BIIB800) and reference tocilizumab before and after switching.1,2 GUANGZHOU, China , Sept. 11, 2024 /PRNewswire/ -- Bio-Thera Solutions, Ltd.

Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE™ (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in Arthritis Research & Therapy

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to treatment due to the new and complicated system associated with taking the drug.

Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley's 22nd Annual Global Healthcare Conference September 4, 2022 10:00 AM ET Company Participants Mike McDonnell – Chief Financial Officer Priya Singhal – Executive Vice President and Head-Development Conference Call Participants Terence Flynn – Morgan Stanley Terence Flynn Okay, great. I think we're going to get started, but thanks for joining us, everyone.

Biogen Inc.'s (BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference Transcript

CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA). The investigational higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA). The study met its primary endpoint at six months, achieving a statistically significant improvement in motor function in infants who received the higher dose regimen as compared to a prespecified matched sham (untreated) control group from the ENDEAR study.

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.

Biogen Stock Declines 20.9% Year to Date: Time to Sell?

Alzheimer's patients in Britain's state-run health service is unlikely to get access to Eisai and Biogen's new Leqembi drug, after it was approved by the country's regulator but deemed too expensive for wide use on Thursday.

News for Biogen Stock (BIIB)